Heartflow (NASDAQ:HTFL) Sets New 52-Week High - Should You Buy?

Heartflow, Inc. (NASDAQ:HTFL - Get Free Report)'s stock price hit a new 52-week high on Thursday . The stock traded as high as $39.45 and last traded at $39.31, with a volume of 514402 shares. The stock had previously closed at $36.64.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Canaccord Genuity Group lifted their price objective on shares of Heartflow from $35.00 to $39.00 and gave the company a "buy" rating in a research report on Monday, September 22nd. Zacks Research upgraded shares of Heartflow to a "hold" rating in a research report on Wednesday, September 3rd. JPMorgan Chase & Co. assumed coverage on shares of Heartflow in a research report on Tuesday, September 2nd. They set an "overweight" rating and a $36.00 price objective on the stock. Piper Sandler assumed coverage on shares of Heartflow in a research report on Tuesday, September 2nd. They set an "overweight" rating and a $38.00 price objective on the stock. Finally, Morgan Stanley assumed coverage on shares of Heartflow in a research report on Tuesday, September 2nd. They set an "equal weight" rating and a $35.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $36.60.

Heartflow Stock Performance

The firm's fifty day simple moving average is $33.27.

Heartflow (NASDAQ:HTFL - Get Free Report) last posted its earnings results on Friday, September 19th. The company reported ($1.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($1.26). The company had revenue of $43.42 million for the quarter, compared to analysts' expectations of $43.20 million.

About Heartflow

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.